Genetic Analysis of COVID-19 Susceptibility and Resistance Determinants in the Collaborative Cross
Genetic Analysis of COVID-19 Susceptibility and Resistance Determinants in the Collaborative Cross
批准号:
10463708
负责人:
Ralph S Baric
金额:
$76.61万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-09-25 至 2025-08-31
关键词:
2019-nCoVAcute Respiratory Distress SyndromeAffectAgeAnimal ModelAntiviral AgentsCOVID-19COVID-19 pathogenesisCOVID-19 pneumoniaCOVID-19 susceptibilityCRISPR/Cas technologyCandidate Disease GeneCessation of lifeCoronavirusCustomDevelopmentDiseaseDisease OutcomeDisease susceptibilityExhibitsFactor AnalysisGenderGenesGeneticGenetic Predisposition to DiseaseGenetic VariationHaplotypesHealthHealthcare SystemsHomeostasisHumanImmuneImmune responseImmunityIndividualInfectionInflammatoryIntegration Host FactorsKnowledgeLaboratoriesLaboratory miceLungMapsMedicalMiddle East Respiratory Syndrome CoronavirusModelingMouse StrainsMusPathogenesisPathway interactionsPatientsPreclinical Drug EvaluationPreclinical TestingPredispositionPublic HealthPulmonary PathologyQuantitative Trait LociResearchResistanceRespiratory physiologyRiskRisk FactorsSARS coronavirusSafetyShapesStatistical ModelsSusceptibility GeneTestingTherapeuticVaccinesVariantVirusVirus DiseasesWorkbasecoronavirus diseasecoronavirus vaccinedisorder riskexperiencegenetic analysisgenomic locushuman modelimprovedinfluenzavirusinsightmalemenmonocytemouse modelnonhuman primatenovel coronavirusnovel vaccinespandemic diseasepathogenphenotypic dataprognostic assaysremdesivirresistant strainrespiratory infection virusresponsesexzoonotic coronavirus
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract:
The 2019 nCoV (SARS-CoV2 or nCoV2) is currently causing a global pandemic, and is on track to cause millions
of infections, hundreds of thousands of deaths, and significantly disrupt healthcare systems and economies
globally. nCoV2 is a group 2B coronavirus that is 75% identical to Severe Acute Respiratory Syndrome
Coronavirus (SARS-CoV), which emerged in 2003. Approximately 10% of nCoV2 infections result in COVID-19
pneumonia that progresses to acute respiratory distress syndrome (ARDS), while a significant fraction of other
individuals are asymptomatic or develop mild disease. While age, gender, and underlying health conditions
predispose individuals to severe disease/death, we have a poor understanding of the factors that drive disease
outcome. This knowledge is essential for understanding the pathogenesis of COVID-19, and for
developing and testing safe and effective nCoV vaccines and therapies. However, while patient studies
can provide insights into the disease risk factors, mechanistic analysis of these factors will require robust animal
models of COVID-19 disease. Unfortunately, nCoV does not replicate in standard laboratory mice, and a
significant need exists for new animal models that reproduce human-like COVID-19 disease, including ARDS.
Collaborative Cross (CC) mice vary significantly in their response to SARS-CoV, and we were able to take
advantage of this variation both to develop new models SARS-CoV-induced disease, while also identifying host
genetic factors that regulate disease outcome. Based on this experience, we propose take advantage of a new
mouse adapted SARS-CoV2 virus (maCoV2), which was recently developed in the Baric laboratory, to screen a
panel of CC mouse strains for susceptibility to maCoV2-induced disease. This work will accomplish two critical
research objectives by: 1) developing critically needed mouse models of nCoV2-induced disease, and 2)
identifying polymorphic host genes/pathways that regulate resistance or susceptibility to nCoV2-disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Core A: Administrative Core
-
批准号:10513680
-
项目类别:
-
资助金额:$920.22万
-
财政年份:2022
-
负责人:Ralph S Baric
-
依托单位:
Development of direct-acting flavivirus inhibitors
-
批准号:10513687
-
项目类别:
-
资助金额:$395.75万
-
财政年份:2022
-
负责人:Ralph S Baric
-
依托单位:
Core B: Virology Core
-
批准号:10425027
-
项目类别:
-
资助金额:$215.31万
-
财政年份:2022
-
负责人:Ralph S Baric
-
依托单位:
Research Project 1: Coronavirus antiviral lead development and combination testing
-
批准号:10513684
-
项目类别:
-
资助金额:$508.76万
-
财政年份:2022
-
负责人:Ralph S Baric
-
依托单位:
RAPIDLY EMERGING ANTIVIRAL DRUG DEVELOPMENT INITIATIVE- AViDD CENTER (READDI-AC)
-
批准号:10513679
-
项目类别:
-
资助金额:$6548.32万
-
财政年份:2022
-
负责人:Ralph S Baric
-
依托单位:
Development of Antivirals against Filovirus Replication
-
批准号:10513686
-
项目类别:
-
资助金额:$379.6万
-
财政年份:2022
-
负责人:Ralph S Baric
-
依托单位:
Systems Immunogenetics of Emerging Coronavirus Infections in the Collaborative Cross
-
批准号:10180497
-
项目类别:
-
资助金额:$10.32万
-
财政年份:2020
-
负责人:Ralph S Baric
-
依托单位:
Human antibody-based countermeasures against the Coronavirus SARS-CoV-2
-
批准号:10264078
-
项目类别:
-
资助金额:$120.62万
-
财政年份:2020
-
负责人:Ralph S Baric
-
依托单位:
Systems Immunogenetics of Biodefense and Emerging Pathogens in the Collaborative Cross
-
批准号:10265701
-
项目类别:
-
资助金额:$9.12万
-
财政年份:2020
-
负责人:Ralph S Baric
-
依托单位:
Project 1: Serological Correlates of SARS CoV2 Immunity and Disease
-
批准号:10688377
-
项目类别:
-
资助金额:$35.01万
-
财政年份:2020
-
负责人:Ralph S Baric
-
依托单位:
North Carolina Seronet Center for Excellence
-
批准号:10855051
-
项目类别:
-
资助金额:$295.01万
-
财政年份:2020
-
负责人:Ralph S Baric
-
依托单位:
Broad-spectrum antiviral GS-5734 to treat MERS-CoV and related emerging CoV
-
批准号:10189984
-
项目类别:
-
资助金额:$45.81万
-
财政年份:2020
-
负责人:Ralph S Baric
-
依托单位:
North Carolina Seronet Center for Excellence
-
批准号:10222240
-
项目类别:
-
资助金额:$397.46万
-
财政年份:2020
-
负责人:Ralph S Baric
-
依托单位:
Core A: Administrative Core
-
批准号:10222241
-
项目类别:
-
资助金额:$51.76万
-
财政年份:2020
-
负责人:Ralph S Baric
-
依托单位:
Antibody Landscape following Human Norovirus Infection and Vaccination
-
批准号:10350601
-
项目类别:
-
资助金额:$73.72万
-
财政年份:2020
-
负责人:Ralph S Baric
-
依托单位:
Genetic Analysis of COVID-19 Susceptibility and Resistance Determinants in the Collaborative Cross
-
批准号:10271310
-
项目类别:
-
资助金额:$76.61万
-
财政年份:2020
-
负责人:Ralph S Baric
-
依托单位:
Systems Immunogenetics of Biodefense and Emerging Pathogens in the Collaborative Cross
-
批准号:10265699
-
项目类别:
-
资助金额:$30.95万
-
财政年份:2020
-
负责人:Ralph S Baric
-
依托单位:
Human antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2
-
批准号:10684696
-
项目类别:
-
资助金额:$119.78万
-
财政年份:2020
-
负责人:Ralph S Baric
-
依托单位:
Genetic Analysis of COVID-19 Susceptibility and Resistance Determinants in the Collaborative Cross
-
批准号:10686223
-
项目类别:
-
资助金额:$76.61万
-
财政年份:2020
-
负责人:Ralph S Baric
-
依托单位:
Respiratory Virus Vaccine and Adjuvant Exploration - Equipment Supplement
-
批准号:10242434
-
项目类别:
-
资助金额:$108.85万
-
财政年份:2020
-
负责人:Ralph S Baric
-
依托单位:
海外基金